Skip to main content

Table 2 Adjusted ORs from MLR: association between anti-CarbV (IgA) and structural damage progression

From: Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN

MLR variable OR Lower CI Upper CI p value
Baricitinib vs. MTX 0.534 0.287 0.970 0.043
Baricitinib + MTX vs. MTX 0.307 0.159 0.574 < 0.001
Baseline anti-CarbV (IgA) 1.002 1.000 1.004 0.051
Baseline ACPA 1.000 0.999 1.000 0.185
Baseline RF 1.000 0.999 1.001 0.724
Erosions at baseline (yes vs. no) 1.516 0.870 2.715 0.150
Baseline hemoglobin 0.796 0.626 1.009 0.061
Baseline hsCRP 1.017 1.008 1.027 < 0.001
Age 1.000 0.981 1.020 0.969
Sex (male vs. female) 0.614 0.282 1.288 0.207
Baseline BMI 0.948 0.897 1.000 0.051
Smoker (yes vs. no) 2.045 1.084 3.825 0.026
Baseline HAQ-DI 0.614 0.389 0.961 0.034
Baseline CDAI 1.022 1.000 1.047 0.062
Europe vs. CSAM 1.423 0.590 3.325 0.421
Japan vs. CSAM 1.132 0.482 2.653 0.775
Rest of the World vs. CSAM 1.068 0.469 2.390 0.874
USA and Canada vs. CSAM 0.627 0.257 1.436 0.283
  1. Adjusted ORs from the MLR model with corresponding 95% CIs and p values. p values < 0.05 were considered statistically significant
  2. ACPA anti-citrullinated protein antibody, BMI body mass index, CarbV carbamylated vimentin, CDAI Clinical Disease Activity Index, CI confidence interval, CSAM Central and South America, HAQ-DI Health Assessment Questionnaire-Disability Index, hsCRP high-sensitivity C-reactive protein, Ig immunoglobulin MLR multivariable logistic regression, MTX methotrexate, OR odds ratio, RF rheumatoid factor